PKARIA (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Human PRKAR1A/PKARIA regulatory subunit of cAMP-dependent protein kinase, expressed in HEK293 cells (UniProt Q9DBC7). Suited for PKA holoenzyme reconstitution, cAMP-binding assays, and antibody validation against matched reagent RP-PKARIA.
Expression system
HEK293
Cat. #
REC-PKARIA

In stock

SKU
REC-PKARIA
$498.00

Target Overview

PKARIA (gene: PRKAR1A; UniProt Q9DBC7) is the type I-alpha regulatory subunit of cAMP-dependent protein kinase (PKA), a central effector of intracellular cAMP signaling. The full-length human protein spans 381 amino acids and functions by binding to the catalytic subunits of PKA, maintaining the holoenzyme in an inactive state until cAMP binding triggers dissociation and catalytic activation. This recombinant form is produced in HEK293 mammalian cells, which supports appropriate folding and post-translational modifications relevant to native PKA regulatory biology. Researchers use this recombinant in several in vitro contexts: reconstitution of PKA holoenzyme complexes for activity and inhibition studies, measurement of cAMP-binding affinity at the two tandem cyclic-nucleotide-binding (CNB) domains, and biophysical characterization of regulatory subunit–catalytic subunit interactions. The HEK293 expression background makes it particularly well suited for pull-down and co-immunoprecipitation experiments where mammalian glycosylation and protein folding are important for interaction fidelity. Because PRKAR1A is broadly expressed and implicated in a range of signaling contexts, the recombinant also serves as a defined positive-control antigen for Western blot and immunohistochemistry antibody validation. Researchers performing antibody qualification with this recombinant can pair it with the matched Triple Point Biologics antibody (SKU: RP-PKARIA), which has been validated for Western blot against human targets. The protein's well-characterized domain architecture — dimerization/docking (D/D) domain, linker region, and two CNB domains — makes it a tractable tool for domain-mapping and allosteric studies of PKA regulation.

Background

The type I-alpha regulatory subunit of cAMP-dependent protein kinase (PKA-RI-alpha, encoded by PRKAR1A) is a principal node in cAMP signal transduction. PKA exists as an inactive tetrameric holoenzyme composed of two regulatory (R) and two catalytic (C) subunits. When intracellular cAMP rises in response to G-protein-coupled receptor activation, cAMP binds cooperatively to the two cyclic-nucleotide-binding domains of the R subunit, inducing a conformational change that releases the catalytic subunits to phosphorylate downstream substrates including transcription factors, metabolic enzymes, and ion channels. PRKAR1A is the dominant regulatory isoform in most cell types and is the primary determinant of PKA type I holoenzyme formation. In published research, PRKAR1A has been studied extensively in the context of allosteric PKA activation. Wu et al. (2025, Protein Sci) characterised how N3A motifs in the RI-beta isoform mediate allosteric crosstalk between cAMP and ATP, work that contextualises the structural dynamics shared across type I regulatory subunits. Recombinant RI-alpha proteins are routinely used as reference standards and binding partners in such biophysical studies. PRKAR1A is also investigated as a research target in oncology. Zhao et al. (2026, Front Immunol) examined PRKAR1B as an oncogenic biomarker in head and neck squamous cell carcinoma, illustrating the broader interest in PKA regulatory subunit biology across tumor types. Loss-of-function variants in PRKAR1A are studied in the context of Carney complex, a multiple endocrine neoplasia syndrome, and the gene is used as a model for understanding tumor suppressor mechanisms downstream of cAMP. On the neurodevelopmental side, PRKAR1B variants have been characterised in Marbach-Schaaf Neurodevelopmental Syndrome (Burkart et al., 2026, Clin Genet), underscoring the research relevance of individual PKA regulatory subunit isoforms in human disease biology. These studies highlight why defined recombinant reagents for each isoform — with known sequence, expression system, and characterisation data — are valuable tools for researchers working to dissect isoform-specific functions. This recombinant PKARIA protein, expressed in HEK293 cells, is suited for use as a biochemical standard in any of these contexts: enzymatic reconstitution, binding assays, structural studies, or antibody validation. Researchers requiring a matched immunodetection reagent can use the Triple Point Biologics antibody RP-PKARIA, validated for Western blot against human PRKAR1A.

Applications

  • PKA holoenzyme reconstitution for in vitro kinase activity assays
  • cAMP-binding affinity measurement using radiolabeled or fluorescent cAMP analogs
  • Inhibitor and activator IC50/EC50 determination in PKA regulatory subunit displacement assays
  • Pull-down and co-immunoprecipitation studies of R-subunit–catalytic subunit or AKAP interactions
  • Antibody validation positive control for Western blot using matched reagent RP-PKARIA
  • Allosteric and biophysical characterization of cyclic-nucleotide-binding domain conformational changes by SPR or ITC
  • Thermal shift assay (DSF/nanoDSF) profiling of ligand-induced stabilization of CNB domains
  • Proteome-level target engagement assays such as sequential denaturation and protein precipitation (SDPP)

References

  1. Zhao P et al. PRKAR1B as an oncogenic biomarker for diagnostic and prognostic stratification of tumor immunity, proliferation, and migration in head and neck squamous cell carcinoma. Front Immunol. 2026. doi:10.3389/fimmu.2026.1770459. PMID: 41798949
  2. Ma Y et al. Sequential denaturation and protein precipitation assay (SDPP) improves the sensitivity for ligand target identification at the proteome level. Anal Chim Acta. 2025. doi:10.1016/j.aca.2025.344722. PMID: 41167885
  3. Burkart S et al. Expansion of the Phenotypic and Genotypic Spectrum for PRKAR1B-Related Marbach-Schaaf Neurodevelopmental Syndrome: A Case Series. Clin Genet. 2026. doi:10.1111/cge.70094. PMID: 41163438
  4. Devaux A et al. Identification of microprotein-coding intronic polyadenylation isoforms and function in genotoxic anticancer drug response. Genome Biol. 2025. doi:10.1186/s13059-025-03829-7. PMID: 41131620
  5. Wu J et al. N3A motifs in RIβ mediate allosteric crosstalk between cAMP and ATP in PKA activation. Protein Sci. 2025. doi:10.1002/pro.70332. PMID: 41108566

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight band should I expect for PKARIA (Recombinant) on SDS-PAGE or Western blot?

The full-length PKARIA protein (381 amino acids, UniProt Q9DBC7) has a calculated molecular weight of approximately 43 kDa. On reducing SDS-PAGE, this HEK293-expressed recombinant typically migrates between 43–47 kDa; slight upward shift from post-translational modifications introduced in the mammalian expression system is normal. Purity is >95% by SDS-PAGE, so a clean, predominant band in that range is expected. If you observe a doublet, this likely reflects phosphorylation heterogeneity rather than a contaminating species.

Is PKARIA (Recombinant) the full-length protein or a truncated regulatory subunit fragment?

This recombinant represents the full-length human PRKAR1A-encoded protein spanning all 381 amino acids, including both tandem cyclic-nucleotide-binding domains (CNB-A and CNB-B) and the dimerization/docking (D/D) domain at the N-terminus. No truncations were introduced. Because it is expressed in HEK293 cells, it carries native-relevant post-translational modifications — important for studies reconstituting intact PKA holoenzyme or characterizing regulatory subunit–catalytic subunit interaction surfaces at physiological fidelity.

What is PKARIA's function in the PKA holoenzyme and how does cAMP trigger its release?

PKARIA is the type I-alpha regulatory subunit that holds the PKA catalytic subunit (Cα or Cβ) in an inactive R2C2 holoenzyme complex under basal cAMP conditions. When intracellular cAMP rises, two cAMP molecules bind cooperatively to the CNB-A and CNB-B domains of each PKARIA subunit, inducing a conformational change that releases active catalytic subunits. This recombinant retains both functional CNB domains, making it directly suitable for fluorescence polarization or ITC-based cAMP-binding affinity measurements and holoenzyme reconstitution assays.

What assay format and starting concentration should I use to measure cAMP binding to recombinant PKARIA?

For fluorescence polarization cAMP-binding assays using a fluorescent cAMP analog (e.g., 8-[Fluo]-cAMP), a starting PKARIA concentration of 50–200 nM works well for Kd determination, given the reported Kd values of ~50–300 nM depending on CNB domain and analog used. Run the assay in 50 mM Tris-HCl pH 7.5, 150 mM NaCl — matching the storage buffer — to avoid rebuffering artifacts. For ITC, 5–10 µM protein in the cell with 100–200 µM cAMP in the syringe is a practical starting point. Titrate protein concentration empirically if signal is low.

What buffer conditions are recommended for PKA holoenzyme reconstitution using this recombinant PKARIA?

The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is compatible with most in vitro reconstitution protocols. For holoenzyme assembly, mix PKARIA with the catalytic subunit (Cα) at an equimolar R:C ratio (typically 0.5–2 µM each) in the same buffer supplemented with 1 mM DTT and 1 mM MgCl₂; incubate 30 min on ice before use. Avoid stripping cAMP from the preparation with high-salt washes before confirming holoenzyme formation by native PAGE or SEC, as the recombinant may carry residual nucleotide from expression.

Can I use PKARIA (Recombinant) as a positive control for Western blot with the matched RP-PKARIA antibody?

Yes — this is one of the primary intended uses. The recombinant PKARIA (REC-PKARIA) and the matched rabbit polyclonal antibody (RP-PKARIA) are produced and validated in the same lab, with guaranteed Western blot compatibility. Load 10–50 ng of recombinant per lane alongside your cell lysate samples; the antibody should detect a clean band at 43–47 kDa. This loading range keeps the recombinant lane within the linear detection window without overwhelming the signal from endogenous PKARIA in your lysate lanes. See the RP-PKARIA product page for recommended antibody dilutions.

How much PKARIA (Recombinant) should I load for a Western blot positive control lane?

10–50 ng per lane is the recommended range when using the matched RP-PKARIA rabbit polyclonal antibody (SKU: RP-PKARIA). Start at 25 ng if you are unsure of your detection system's sensitivity. At >90% purity, virtually all loaded protein contributes to the target band at 43–47 kDa, so this amount produces a robust, interpretable signal without requiring large volumes of your aliquot. If co-running with cell lysates, loading 25 ng recombinant alongside 20–30 µg total lysate gives a comparable signal intensity for most anti-PKARIA antibody dilutions.

How should I store and handle PKARIA (Recombinant) to preserve activity across multiple experiments?

Store at -20°C in the supplied single-use aliquots. The 10% glycerol in the storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl) provides cryoprotection and supports stability through at least 12 months when stored correctly. Avoid repeated freeze-thaw cycles — each cycle risks partial unfolding of the CNB domains, which can reduce cAMP-binding capacity and holoenzyme reconstitution efficiency. On the day of use, thaw on ice, briefly centrifuge at 10,000 × g to pellet any aggregates, and keep on ice during the experiment. Do not dilute the working stock further than necessary until immediately before use.

Validation imagery coming soon

Western blot validation figures for REC-PKARIA will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →